Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain
Authors:
- 1 September 2016
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 50, 265-272
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Clinical Outcome Assessments: Conceptual Foundation—Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task ForceValue in Health, 2015
- Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2015
- Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority StudyClinical Infectious Diseases, 2014
- Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trialThe Lancet Infectious Diseases, 2014
- Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin InfectionNew England Journal of Medicine, 2014
- Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin InfectionsNew England Journal of Medicine, 2014
- Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure InfectionsJAMA, 2013
- Patient reported outcomes: looking beyond the label claimHealth and Quality of Life Outcomes, 2010
- Global Rating of Change Scales: A Review of Strengths and Weaknesses and Considerations for DesignJournal of Manual & Manipulative Therapy, 2009
- Clinical Importance of Provider-Reported HIV Symptoms Compared With Patient-ReportMedical Care, 2001